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While carbapenemases aredisseminatingworldwide inEntero-bacteriaceae, and particularly in Escherichia and Klebsiella
pneumoniae (1), therapeutic options increasingly rely on very few
choices (2). Although colistin and tigecycline are now considered
last-resort antibiotics for treating infections caused by carbapen-
emase producers, aminoglycosides may still be considered valu-
able treatment options, with amikacin remaining quite often
active (3). While broad-spectrum -lactamases such as extended-
spectrum -lactamases (ESBLs) or carbapenemases are spreading
rapidly worldwide, the emergence of acquired 16S rRNA methyl-
ases has been also noticed (4). Those enzymes do confer high-level
resistance to almost all aminoglycosides. The most frequent 16S
rRNAmethylases in Enterobacteriaceae are ArmA, RmtB to RmtF,
and NpmA (4, 5). Those enzymes exhibit signiﬁcant amino acid
heterogeneity, sharing similar amino acidmotifs but being overall
distantly related. Nevertheless, they all confer the same type of
resistance, whereas NpmA confers additional resistance to neo-
mycin and apramycin (5).
Here, we report on a 22-year-old male patient who was admit-
ted at the intensive care unit of the PuertoMontt Hospital located
in Santiago, Chile, on 30 June 2012 for a traumatic subdural
hematoma of the occipitotemporal region. He underwent surgery
and was mechanically ventilated. Ceftriaxone and metronidazole
were prescribed for 7 days (during which time cultures remained
negative) as empirical treatment for pneumonia. Ten days after
his admission, bronchial aspirate samples grew ceftriaxone-resis-
tant K. pneumoniae, while an isolate with the same resistant pat-
tern was recovered from his central venous catheter 3 days later.
Therefore, ceftriaxone treatment was discontinued and switched
tomeropenem, and the patient was ﬁnally discharged after a good
clinical response. Susceptibility testing performed and interpreted
according to the updated CLSI guidelines (6) showed that it was
resistant at a high level to all aminoglycosides (MICs of 256
g/ml for amikacin, gentamicin, and tobramycin) and to most
broad-spectrum -lactams (MIC of cefotaxime and cefepime at
256 g/ml, MIC of ceftazidime at 8 g/ml). It remained suscepti-
ble to carbapenems (MICs of imipenem and meropenem at 0.5
and 1 g/ml, respectively), and the Carba NP test remained neg-
ative (7). In addition, isolate 921 was resistant to tetracycline,
chloramphenicol, sulfonamides, and to all tested ﬂuoroquinolo-
nes. It remained susceptible to tigecycline (MIC of 1 g/ml) ac-
cording to EUCAST breakpoints (8), but the MIC of colistin was
high as determined by Etest (4 g/ml). According to the pheno-
typic test results (synergy between aztreonam and clavulanate), K.
pneumoniae isolate 921 produced an ESBL.
PCR and sequencing performed as described previously (9)
revealed that K. pneumoniae isolate 921 harbored the blaCTX-M-2
ESBL gene, in addition to the blaTEM-1 and blaSHV-11 narrow-spec-
trum -lactamase genes. Since isolate 921 was resistant at a high
level to all aminoglycosides, screening for 16S RNA methylase
genes was performed as reported (10). It failed to identify any
known 16S rRNAmethylase-encoding gene. Therefore, a shotgun
cloning experiment was attempted as described previously (11),
and selection of recombinant Escherichia coli strains was based on
amikacin (30 g/ml) and gentamicin (30 g/ml). Recombinant
strains expressing resistance to all aminoglycosides were obtained,
suggesting the expression of a 16S rRNAmethylase. Sequencing of
the recombinant plasmid identiﬁed a putative open reading frame
encoding a protein sharing 58% amino acid identity with the 16S
rRNAmethylase RmtD.However, it has a perfect identity with the
newly described RmtG which was published while this study was
in progress (12). The rmtG gene encoding high-level resistance to
all aminoglycosides has been identiﬁed in a series of ﬁve K. pneu-
moniae isolates from Brazil, four coproducing the carbapenemase
KPC-2, and all coproducing an ESBL of the CTX-M type (CTX-
M-2, CTX-M-15, or CTX-M-59) (12).
Mating-out assays were performed as described previously
(11) but remained unsuccessful. Therefore, an electrotransforma-
tion experiment was performed using a selection based on amika-
cin and gentamicin or on cefotaxime (30 g/ml). It allowed us to
obtain an E. coli transformant expressing RmtG, exhibiting resis-
tance to all aminoglycosides, to sulfonamides, and to tetracycline
but remaining susceptible to all -lactams, and another type of E.
coli transformant expressing CTX-M-2 and TEM-1. The rmtG-
positive transformant harbored a single 80-kb plasmid that was of
IncA/C type as identiﬁed by PCR-based replicon typing (13). The
blaCTX-M-2-positive transformant harbored a single 170-kb plas-
mid that was not typeable.
Multilocus sequence typing was performed as described previ-
ously (14), and results were analyzed by eBURST (http://pubmlst
.org). It showed that isolate 921 belonged to the ST11 sequence
type, whereas the sequence types of the RmtG-positive K. pneu-
moniae isolates from Brazil were 340, 442, and 1046 (12). How-
ever, in the same study, Bueno et al. identiﬁed several ST11 isolates
expressing the RmtD2 methylase (12).
Address correspondence to Patrice Nordmann, patrice.nordmann@unifr.ch.
1
Published in $QWLPLFURELDO$JHQWVDQG&KHPRWKHUDS\
GRL$$&
which should be cited to refer to this work.
ht
tp
://
do
c.
re
ro
.c
h
Of note, the patient did not receive any aminoglycoside-based
treatment before or after his admission. Therefore, selection of
this aminoglycoside-resistant isolate remains intriguing. Itmay be
speculated that clones or plasmids carrying the rmtG gene are
disseminating in SouthAmerican countries such as Chile andBra-
zil (12). Occurrence of multidrug-resistant strains is extremely
worrisome, and there is an urgent need to implement adequate
screening strategies in order to control their spread. This study
underlines that a focus on emerging antibiotic resistance mecha-
nisms in Gram negatives shall be made not only for broad-spec-
trum -lactams but also for broad-spectrum aminoglycosides,
since both types of resistance will contribute to the emergence of
pan-drug resistance.
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